| Jul 8 |
IPO Roundup: Actuate Therapeutics, Autozi Internet, and more
|
| Jul 8 |
Brainstorm Cell Therapeutics Inc. (BCLI) Corporate Mid-Year Update on NurOwn Program (Transcript)
|
| Jul 1 |
BrainStorm Cell Therapeutics to Provide Corporate Mid-Year Update on NurOwn Program
|
| Jun 27 |
BrainStorm Cell Therapeutics announces pricing of $4M registered direct offering
|
| Jun 27 |
BrainStorm Cell Therapeutics Announces Pricing of $4.0 Million Registered Direct Offering
|
| Jun 26 |
BrainStorm Cell Therapeutics Reaches Alignment with FDA on CMC Aspects of Phase 3b NurOwn® Clinical Trial
|
| Jun 20 |
BrainStorm appoints Haro Hartounian as COO
|
| Jun 20 |
BrainStorm Cell Therapeutics Announces Appointment of Haro Hartounian Ph.D. as Chief Operating Officer
|
| Jun 14 |
BCLI: Initiation - Potential 10x Return on Successful Phase 3b. Promising Post Hoc and Biomarker Analysis Underpins Our NurOwn® Clinical Effectiveness Expectation
|
| May 20 |
BrainStorm Cell Therapeutics to Present New Biomarker Data Suggesting ALS Patients May Benefit From Longer-Term Treatment with NurOwn
|
